Form 4: C4 Therapeutics Director Acquires Shares in Lieu of Cash Compensation

Donna Roy Grogan, a director at C4 Therapeutics, acquired 2,474 shares of common stock in lieu of cash compensation on October 1, 2024.

Summary

• On October 1, 2024, Donna Roy Grogan, a director of C4 Therapeutics, Inc. (CCCC), acquired 2,474 shares of the company's common stock.
• The acquisition was made in accordance with the Issuer's Non-Employee Director Compensation Policy.
• Grogan elected to receive shares of CCCC common stock in lieu of cash compensation for services as a non-employee director.
• The price per share was $5.56, based on the closing market price of CCCC common stock on October 1, 2024.
• Following the transaction, Grogan directly owns 28,942 shares of C4 Therapeutics.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. A director taking shares instead of cash is generally seen as a good sign, indicating confidence in the company's future.

Positives

• A director's decision to take compensation in stock aligns their interests with those of shareholders.

Industry Context

Directors receiving stock in lieu of cash compensation is a common practice to align management's interests with shareholders, particularly in growth-oriented companies.

Stakeholder Impact

• The transaction could have a slightly positive impact on shareholders as it aligns the director's interests with theirs.

Key Dates